Diagnostic accuracy and reliability of susceptibility map-weighted imaging in patients with clinically uncertain parkinsonian syndromes.
Authors
Affiliations (8)
Affiliations (8)
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, location Universiteit Amsterdam, Amsterdam, The Netherlands. [email protected].
- Department of Neurology, Amsterdam UMC, location Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, location Universiteit Amsterdam, Amsterdam, The Netherlands.
- Queen Square Institute of Neurology and UCL Hawkes Institute, University College London, London, UK.
- Department of Neurology, Spaarne Gasthuis Hospital, Haarlem, The Netherlands.
- Department Neurology, Flevoziekenhuis Hospital, Almere, The Netherlands.
- Department of Neurology Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Abstract
Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra, accompanied by increased iron accumulation, particularly in the nigrosome-1 subregion. Differentiating neurodegenerative disorders like PD from non-neurodegenerative causes of parkinsonism can be challenging. In clinically uncertain parkinsonian syndrome (CUPS), dopamine transporter (DAT)-single-photon emission computed tomography (SPECT) can aid diagnosis. However, susceptibility map-weighted imaging (SMWI) provides a promising magnetic resonance imaging (MRI) alternative. We evaluated the diagnostic accuracy and reliability of visual SMWI assessment by radiologists in CUPS and the added value of artificial intelligence (AI)-driven diagnostic software. Patients with CUPS who underwent DAT-SPECT between January 2019 and July 2023 were included. Four radiologists, blinded to clinical symptoms and diagnosis, visually rated nigrosome-1 on axial SMWI reconstructions as normal, unclear, or abnormal. After the initial assessment, the radiologists re-evaluated the scans with AI-driven software assistance, designed to classify and quantify nigrosome-1 integrity. The reference standard was the final clinical diagnosis incorporating DAT-SPECT results. One hundred eighty patients were included (mean age 67.9, range 31-86, 120 males), 84 with neurodegenerative and 96 with non-neurodegenerative parkinsonism. Mean diagnostic accuracy was 80% (range 73-83%), with substantial inter-rater reliability (Fleiss κ 0.65). With software assistance, diagnostic accuracy improved to 87% (range 85-91%), and inter-rater agreement increased to almost perfect (Fleiss κ 0.86). SMWI, particularly with AI-driven software assistance, is a promising and accessible MRI-based technique that may support the diagnostic workup in clinically uncertain parkinsonism, aiding the distinction between neurodegenerative and non-neurodegenerative causes. Question Can susceptibility map-weighted imaging (SMWI) reliably differentiate neurodegenerative from non-neurodegenerative parkinsonism in clinically uncertain cases, and does artificial intelligence (AI)-driven software assistance improve radiologist performance? Findings Visual assessment had an accuracy of 80%, with substantial inter-rater reliability. AI-driven software assistance increased accuracy to 87% and improved inter-rater reliability. Relevance statement SMWI can differentiate neurodegenerative from non-neurodegenerative parkinsonism in clinically uncertain cases and may support the diagnostic process by offering an accessible MRI-based technique, facilitating an efficient diagnostic workup, and enabling early diagnosis in clinically uncertain parkinsonism.